In Vivo Activity of Norhydrocodone: An Active Metabolite of Hydrocodone

  title={In Vivo Activity of Norhydrocodone: An Active Metabolite of Hydrocodone},
  author={Dipesh M. Navani and Byron C. Yoburn},
  journal={The Journal of Pharmacology and Experimental Therapeutics},
  pages={497 - 505}
  • Dipesh M. NavaniB. Yoburn
  • Published 1 November 2013
  • Biology, Medicine
  • The Journal of Pharmacology and Experimental Therapeutics
Hydrocodone is primarily metabolized to hydromorphone and norhydrocodone. Although hydromorphone is a known active metabolite of hydrocodone, the in vivo activity of norhydrocodone is not well documented. In the current study, the pharmacodynamics of norhydrocodone were evaluated and compared with hydrocodone and hydromorphone. Binding studies established that norhydrocodone, similar to hydrocodone and hydromorphone, is a μ-selective opioid ligand. In vivo analgesia studies (tail flick… 

Figures and Tables from this paper

Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone

Two studies show that there is a metabolic component of tolerance to oxycodone; however, the reversal of that tolerance by ethanol is not due to an alteration of the biodisposition of oxy codone, but rather is neuronal in nature.

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers

While there was no evidence of “dose-dumping” (an unintended, rapid release in a short time period of all or most of the hydrocodone from HC-ER), even with 40% alcohol, as with all opioids, alcohol should not be ingested while using HC- ER.

Lack of Influence by CYP3A4 and CYP3A5 Genotypes on Pain Relief by Hydrocodone in Postoperative Cesarean Section Pain Management.

It is confirmed that CYP2D6 phenotypes are predictors for plasma hydromorphone concentration and pain relief, but CYP3A4/A5 phenotypes have no influence on pain relief or on side effects.

Feasibility and Utility of the Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.

The results demonstrate that pharmacogenetics afford clinicians an opportunity to individualize HC dosing, while adding enhanced opportunity to account for its conversion to HM in the body, which indicates HC has significant phenotype-dependent prodrug effects.

Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.

The time course of OC and metabolites, noroxycodone (NOC), oxymorphone (OM) and noroxymorphones (NOM), in near-simultaneous paired OF and whole blood (BL) specimens by liquid chromatography-tandem mass spectrometry (LC-MS-MS) is demonstrated.

Endogenous opiates and behavior: 2013

Understanding the Agent, Part III: Specific Drugs

The old injunction to “know a few agents really well” is certainly reasonable; however, staying abreast of the current knowledge base is essential when prescribing potentially lethal agents and those that can otherwise ruin a life.

A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products

When adding a new medication to an ARV regimen, use of a drug-drug interaction software and/or consultation with a clinical pharmacist/pharmacologist or HIV specialist is recommended.



Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers.

Although hydromorphone was found at lower levels than hydrocodone, in six of seven subjects, it persisted for as long as hydrocdone was detected, thus making the nor-metabolite a valuable tool in evaluating hydrocidone use and/or misuse.

Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats.

Data suggest that differences in CYP2D6 phenotype will have limited influence on the drug response to hydrocodone after nonoral administration, verified in a study showing that inhibition of hydrocODone biotransformation to hydromorphone does not affect measures of abuse liability.

Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability.

The data suggest only a small role of hydromorphone in eliciting abuse-related responses to oral hydrocodone, and quinidine had no consistent effect on their responses, even thoughQuinidine abolished the pre-existing metabolic differences in hydrom orphone production, as measured in urine.

Effect of Cytochrome P 450 2 D 1 Inhibition on Hydrocodone Metabolism and its Behavioral Consequences in Rats 1

Data suggest that differences in CYP2D6 phenotype will have limited influence on the drug response to hydrocodone after nonoral administration, and this has recently been verified in a study showing that inhibition of hydrocODone biotransformation to hydromorphone does not affect measures of abuse liability.

CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone

The data establish the importance of CYP2D6 in the formation of hydromorphone from hydrocodone and suggest that the activity of this enzyme may limit the abuse liability of hydrocODone.

Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer

Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors

7,8-saturated codeine congeners are more efficacious than codeine, which may explain their lack of requirement for 3-O-demethylation in vivo, and further research is needed to understand the relationship between metabolism and in vivo activity of these compounds.

CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

The O-demethylation of hydrocodone is predominantly catalyzed by CYP2D6 and to a lesser extent by an unknown low affinity cytochrome p450 enzyme, and the genetic polymorphisms of CYP 2D6 may influence hydromorphone metabolism and its therapeutic efficacy.